Detalles de la búsqueda
1.
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38755516
2.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696053
3.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578596
4.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649648
5.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 559-563, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538963
6.
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
Breast Cancer;
31(3): 335-339, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38433181
7.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 551-558, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526621
8.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol;
29(5): 535-544, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494578
9.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol;
29(5): 545-550, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517658
10.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(4): 355-362, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38353907
11.
IL25+ macrophages are a key determinant of treatment resistance of IL17RB+ breast cancer.
Am J Cancer Res;
13(10): 4931-4943, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37970362
12.
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Breast Cancer;
30(6): 872-884, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37804479
13.
Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial.
Front Oncol;
13: 1216813, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37483483
14.
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).
BMJ Open;
13(4): e070304, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37012013
15.
[Challenges to International Collaborative Clinical Research and Approval Disparities].
Gan To Kagaku Ryoho;
50(1): 30-34, 2023 Jan.
Artículo
en Japonés
| MEDLINE | ID: mdl-36759982
16.
Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin.
Breast Cancer Res;
25(1): 21, 2023 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36810117
17.
The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor-positive breast cancer: A single-institute retrospective study.
Cancer Rep (Hoboken);
6(2): e1695, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36806718
18.
Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer.
Breast Cancer Res Treat;
196(2): 341-348, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36153381
19.
Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer.
Data Brief;
45: 108558, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36118297
20.
Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories.
J Breast Cancer;
25(3): 207-217, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35657002